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The concept of prophylaxis of infective endocarditis has changed substantially in recent
years; currently, prophylaxis is recommended only in patients at highest risk of developing
infective endocarditis who are scheduled for dental procedures involving the gingiva. The
risk is also increased in individuals with pacemakers and implantable cardioverter/
deﬁbrillators. Other high-risk populations include polymorbid patients (diabetes mellitus
or chronic hemodialysis), the elderly (particularly those aged 75–79 years), and males. In
indicated cases, the drugs used in prevention include amoxycillin or ampicillin.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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eases. In untreated patients, it is associated with 100%
mortality, with in-hospital mortality being some 20% (despite
the currently high standard of its diagnosis and treatment
including cardiac surgery) [1,2]. While generally considered a
rare disease, its incidence, though stable (also in the Czech
Republic), is by no means negligible [3,4]. Data from a recent
large French study show that IE occurs in 33.8 per 1 mil pop.
[5]. The pattern of IE patients has also evolved, with elderly
men now making up the largest patient population, as has
the spectrum of causative agents (see below).ch Society of Cardiology.It follows from the above that the pivotal role in IE
management is played by timely optimal therapy, with
antibiotic prophylaxis, ﬁrst proposed as early as 1955, being
just an alternative approach [6]. Until recently, prophylaxis
was indicated in patients at risk of developing IE while
scheduled for a variety of procedures [7,8] involving the oral
cavity, airways, cardiovascular system, gastrointestinal and
urogenital tracts, and conditions including skin diseases and
a wide range of congenital and acquired heart (primarily
valve) diseases. However, the concept of IE prophylaxis has
changed dramatically in recent years and the current list ofPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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revised and shortened.
It should be noted that the paradigm of IE prophylaxis was
created and maintained on the basis of observational studies
conducted in the early 20th century. The principal hypothesis
was based on the assumption that bacteremia developing
after a common procedure in at-risk patients may lead to the
development of IE. There is also evidence that the bacteremia
can be inﬂuenced by an antibiotic, as documented by experi-
mental data [9]. While, essentially, these concepts have not
become completely invalid since, a number of facts have
emerged that actually make them somewhat obsolete. That
was why the Task Force of the European Society of Clinical
Microbiology and Infectious Disease and the International
Society of Chemotherapy in Infections and Tumors jointly
developed a document endorsed by the European Society of
Cardiology addressing the issue of infective endocarditides
[9]. The document markedly shortened the list of indications
for antibiotic prophylaxis. Even more radical were the 2007
American Heart Association (AHA) guidelines [10,11] ruling
out prophylaxis before gastrointestinal and urogenital proce-
dures while recommending it only in patients at the highest
risk of IE and scheduled for dental procedures. The most
radical British (National Institute for Health and Clinical
Excellence, NICE) guideline published a year later completely
dismissed the concept of IE prophylaxis [12].
Recommendations for antibiotic prophylaxis most often
apply to procedures in the oral cavity although there have
also been occasional doubts whether or not streptococcal IE
may actually develop via this pathway [13,14]; however, this
possibility was documented by other studies [15]. In dental
procedures involving the gingiva, and during everyday pro-
cesses occurring in the mouth, bacteremia is present over a
large range of 10–100% [16]; however, its impact on the
development of IE is different in the completely healthy
population and in individuals at risk of developing IE. In
absolute numbers, the risk of IE in dental procedures is 1 per
14,000,000 in the general population while increasing drama-
tically to 1 per 95,000 in those with previous IE [17,18]. On the
other hand, transient bacteremia will be detected during
common processes occurring in the mouth such as tooth
brushing and chewing [16,19]. Some data even suggest that
everyday bacteremia occurs six million times more often
than the bacteremia associated with single-tooth extraction
[20]. In individuals with poor oral hygiene, bacteremia will
develop independently of any procedures and everyday
processes in the oral cavity [21]. In a large proportion of
patients currently diagnosed with IE, bacteremia is not pre-
ceded by any clearly identiﬁable cause; hence, its source may
be completely different from the suspected one [22]. Alter-
natively, is it possible that antibiotic prophylaxis is simply
ineffective in new-onset IE treated with proper prophylaxis?
Perhaps either possibility is partly true.
Moreover, antibiotic administration – particularly on a
broader scale – is not devoid of risk. The spectrum of
organisms resistant to certain antibiotics is expanding.
Besides, antibiotic use is associated with the risk – albeit
rather small – of anaphylaxis, and no lethal complication has
been reported to date in connection with the administration
of amoxycillin in the prevention of IE [23].However, the main challenge in pharmacological prophy-
laxis of IE is that it has never been conclusively shown to be
effective and the currently available results are fairly con-
troversial. There is a complete lack of evidence showing that
antibiotic-induced changes in the frequency or duration of
bacteremia would impact the incidence of IE [9]. In the past,
the typical IE patient was one with a predisposing valve
disease who developed streptococcal endocarditis. However,
this belief is no longer valid as IE has been shown not to be
associated solely with a previous heart disease; moreover, its
etiology in most patients is not streptococcal [2]. Still, it
should be remembered that no large randomized controlled
trial that could possibly provide a plausible answer has been
conducted to date. An exception to this is the study by
Lockhart and colleagues [16] investigating bacteremia in their
290 patients randomized into three groups: simple tooth
brushing, tooth extraction with amoxicilin-based prophy-
laxis, or tooth extraction with placebo. Bacteremia was
detected in 23% patients of the ﬁrst group, 33% in the
amoxicillin-based prophylaxis group, and in 60% of patients
not receiving antibiotic prophylaxis. While, in light of all the
above facts and studies, the earlier guidelines (including our
past ones) [7,8] can obviously be considered obsolete,
straightforward exclusion of antibiotic prophylaxis in the
British NICE guideline [12] is unlikely to be a reasonable
approach; based on our current knowledge, it just represents
the other extreme which should not be adopted [9].
As formulated in the latest European guidelines, the
prerequisites for IE prevention can be summarized in two
main principles [9]: in IE prophylaxis, to focus attention on
patients and procedures associated with the highest risk, and to
maintain good oral hygiene. The European guidelines are a
well-balanced document, which puts the radical British
guideline [9] disapproving any prophylaxis in opposition
against the “rest of the world” [1].
As regards IE, at-risk patients can be divided into three
categories [9].(1) Individuals with prosthetic valves or any other prosthetic
material employed for surgical correction of heart valve
disease;(2) Patients with a history of IE;
(3) Patients with complex congenital heart disease, cyanotic, not
corrected surgically or those with residual shunts,
implanted palliative shunts, conduits, or other types of
prostheses. This category includes cases of congestive
heart disease managed with a prosthetic material within
6 months (as endothelization is complete after 6 months
and there is no longer any need for prophylaxis), persis-
tent shunts following the implantation of the most varied
types of materials using catheter-based or cardiac surgery
procedures.In the US guidelines, the third category includes heart
transplant recipients developing valve dysfunction [11]; how-
ever, this indication is not supported by conclusive evidence.
On the other hand, most cases of IE have recently been
shown to occur in individuals without any pre-existing heart
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 5 2 0 – e 5 2 4e522disease [1,5]. The population at highest risk for developing IE
are the elderly, with the incidence of IE peaking in the 75–79
age group (an up to tenfold increase in incidence), particularly
among males [1,5]. It is also more frequent among polymor-
bid patients (with hypertension, diabetes mellitus, and those
on chronic hemodialysis) [1].
Procedures carrying the risk of IE development [9].
These include, without any doubt, dental procedures invol-
ving manipulation the gingiva, periapical structures, and any
injury to mucosal integrity (its perforation). This category
does not include procedures involving the respiratory, gastro-
intestinal, or urogenital tracts, skin and soft tissue. In these
cases, prophylaxis is not performed on a routine basis, except
for high-risk patients undergoing a procedure where infection
can reasonably be anticipated such as pulmonary abscess
draining [9,19].
Some more recent studies [1] have suggested a pacemaker
or an implantable cardioverter/deﬁbrillator (ICD) may be
associated with a higher risk for IE than originally believed.
In a recent large multicentrer international prospective trial
[24] following up 2760 patients, this type of IE was found in
177 individuals (more than 6%). The predominant type of
infection was staphylococcal (Staphylococcus aureus in 35%,
coagulase-negative staphylococcus in 32%). A most frequent
ﬁnding was involvement of valve structures (particularly the
tricuspid valve), with in-hospital and one-year mortality rates
being close to 15% and 23%, respectively [24]. Signiﬁcantly
more favorable one-year mortality rates (20%) were reported
for patients who had their whole system removed already
during their ﬁrst hospitalization compared with those who
had not [24].
As suggested by a large prospective, randomized, placebo-
controlled study, antibiotic prophylaxis may indeed confer
protection to patients scheduled for implantation [25]. In this
study, a total of 1000 implantation candidates were rando-
mized to receive either prophylactic cefazolin or placebo
infusion. The originally six-month study had to be stopped
prematurely for signiﬁcantly higher infection rates in the
placebo arm; this outcome became reﬂected in the AHA
guidelines, which were complemented with recommendation
of prophylaxis before implant procedures [26]. At present, it is
recommended to administer anti-staphyloccocal antibiotics,
that is, ﬁrst-generation cephalosporins (cefazolin) or vanco-
mycin [1,26].
It should be emphasized in this context that there has
been a steady rise in the rates of IE occurring in health care
facilities (health care-associated IE), that is, nosocomial infec-
tions [2]. The typical microbes are both Staphylococcus aureus
and coagulase-negative staphylococci described below andTable 1 – Prophylaxis in risk-related dental procedures [9].
Single d
Adults
Amoxicillin or ampilicilin 2 g p.o.
Clindamycinn 600 mg
n Administered in patients with an allergy to penicillin or ampicillin.detected most often in elderly polymorbid patients (diabetes
mellitus, hypertension, chronic hemodialysis) [1]. These
patients do not necessarily include only those hospitalized
but, also, outpatients (hemodialysis, intravenous chemother-
apy). Some authors [27] have suggested this population
represents up to 30% of IE cases and their prognosis is worse
than that of patients with community-acquired IE [28].
High-risk microbes: They are primarily staphylococci caus-
ing over 36% of cases of IE [5]. The largest proportion of IE
cases is caused by Staphylococcus aureus (26%) while the
remaining 10% are caused by coagulase-negative staphylococci [5].
Staphylococcal infections tend to occur more frequently
not only in addicts but, also, in hemodialysis and
immunosuppressive-treated hospitalized patients scheduled
for a variety of cardiac surgery procedures, implantation of
pacemakers and similar devices; the proportion of individuals
with a pre-existing heart disease in this population is usually
smaller [29]. The frequent presence of these microbes in the
etiology of IE led to the addition of Staphylococcus aureus as a
typical microbe to the Durack criteria in 2000 [30]. The
incidence of IE caused by Staphylococcus aureus rose from 5.2
cases in 1991 to 8.2 cases per one mil/pop. [1], with staphy-
lococcal etiology considered one of the markers of a more
serious prognosis [31]. As a result, procedures shown to be
associated with the occurrence of this microbe (prosthetic
valve and pacemaker implantation as well as chronic hemo-
dialysis and diabetes mellitus) are potentially more
challenging.
The issue of prosthetic staphylococcal IE was addressed in
detail by a large multicenter international study [32] involving
537 patients with prosthetic valve endocarditis. Infective
endocarditis caused by coagulase-negative staphylococci
was detected in 16% of study participants, with half of them
developing IE within 60–365 days after valve implantation. In
a high proportion of cases (approx. 50%), IE was associated
with abscess formation; IE caused by methicillin-resistant
staphylococci was frequent (68%) [32]. In-hospital mortality
related to coagulase-negative IE was 24% (36%with Staphylococcus
aureus and 9% with viridans streptococci). A special case was
recently reported with IE caused by Staphylococcus lugdunensis [33].
While rare, it is a form typically associated with extensive valve
destruction and abscess formation, and poorly responding to
antibiotic therapy [34].
According to the latest European guidelines, IE prophy-
laxis should only be performed in patients who are at highest
risk and scheduled for dental procedures speciﬁed above [9].
The technique of IE prophylaxis is summarized in Table 1.
All the listed antibiotics should be administered, at a single
dose, 30–60 min preprocedurally [9]; the procedure is targetedose 30–60 min prior to procedure
Children
or i.v. 50 mg/kg p.o. or i.v.
p.o. or i.v. 20 mg/kg p.o. or i.v.
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cocci (oxacilin, vancomycin) can be used in disposed persons
to cover procedures connected with pyogenic infection of
skin and soft tissues.
As an exception, prophylaxis can also be undertaken in
procedures other than the dental ones (see above). In such
cases, it is recommended to use an antistaphylococcal peni-
cillin or cephalosporin (e.g., in lung abscess draining, proce-
dures involving skin abscesses or other purulent affections),
vancomycin in MRSA, anti-enterococcal antibiotics in proce-
dures involving the gastrointestinal tract (ampicillin, amox-
ycillin, vancomycin). Antibiotic prophylaxis is not mandatory
in individuals at increased risk of IE who have piercing- or
tattoo-related procedures as long as these are performed
under strictly aseptic conditions [9]; however, this position
may be revised (there have been case reports, albeit uncon-
vincing, suggesting the potential for developing IE, e.g., after
tongue piercing) [35].
Another quite serious and different issue is that related to
patients presenting for valve replacement or implantation of
a man-made material into the valve or blood vessels. These
patients are at risk of developing early IE (within one year
post-implant) caused by Staphylococcus aureus or coagulase-
negative staphylococci. The recommendation is to perform
prophylaxis immediately prior to the procedure; in the case of
prolonged procedures, the antibiotic should be administered
also post-operatively withdrawing it until 48 h after the
procedure [9].
Is it possible to assess the impact of new guidelines on the
incidence of IE in at-risk patients? This is a most intriguing
question, although several hints have already emerged.
Between 2000 and 2008, when the old guidelines were still
in effect, there was a trend towards an increase in the
number of cases of IE in the United Kingdom [36]. On the
other hand, after the guidelines were substantially revised in
2008 dramatically reducing prophylactic prescription and use
of antibiotics (with the British NICE guideline completely
dismissing prophylaxis), the incidence of IE in the United
Kingdom remained almost unchanged [36]. The French AEPEI
(Association pour l'Etude et la Prévention de l'Endocardite
Infectieuse) trial reported a similar phenomenon [1].
There is little doubt that the characteristics of IE as we
know it today have changed substantially compared with
what it was in the past. The disease affects increasingly more
elderly individuals, primarily polymorbid patients with a
variety of implanted devices [1]. In these individuals, anti-
biotic prophylaxis seems to be most appropriate [1]. Strepto-
cocci as the predominant causative agents have been
replaced by staphylococci. It should always be remembered
that most current guidelines are based on conclusions and
consensuses of experts or on results of observational or
experimental studies, while not actually incorporating data
from evidence-based medicine. Hence, another revision of
the guidelines should be reasonably expected, although one
can only speculate about the extent of the changes [1,37].
In conclusion, it should be noted that concepts regarding
IE prevention have witnessed substantial changes in recent
years and “prevention is not as simple as in the good old
days” [2]. The list of patients and procedures with recom-
mended antibiotic prophylaxis has become shorter. Antibioticprophylaxis is currently recommended only in patients at
highest risk of developing infective endocarditis, that is,
those scheduled to receive a prosthetic valve, patients with
some types of complex congenital heart disease, implanted
palliative shunts, conduits or prostheses as well as indivi-
duals with a history of IE. Those at highest risk include
elderly and polymorbid patients (diabetes mellitus); the
incidence of IE is currently not associated with a previous
heart disease in most patients. Prophylaxis should be per-
formed prior to dental procedures involving the gingiva and
implantation of pacemakers and similar devices (ICD). Pro-
phylaxis with amoxycillin or ampicillin at a dose of 2 g is
administered 30–60 min preprocedurally; patients with
allergy are given clindamycin whereas ﬁrst-generation
cephalosporins or vancomycin are used in patients scheduled
for pacemaker or ICD implantation. Critical preventive mea-
sures in patients at high risk of IE include careful oral hygiene
with regular dental checkups combined with maintenance of
strictly sterile conditions during all risk-related procedures
(pacemaker implantation and similar).
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